Rhegen

About Rhegen

Rhegen Bio, also known as Shenzhen Rhegen Biotechnology Co., Ltd., is a biopharmaceutical company founded in 2019 by Dr. Yong Hu. Dr. Hu received his Ph.D. from Wuhan University in 2012, followed by postdoctoral research at Harvard University where he first engaged with mRNA technology and its therapeutic potential. In 2018, he returned to China as a Principal Investigator (PI) and doctoral supervisor at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, before establishing Rhegen Bio a year later.

The company operates as a platform-centric technology firm, concentrating on the development of innovative mRNA drugs and vaccines. It has established a vertically integrated R&D system, giving it control over the entire development chain, from initial drug target discovery and molecular design to drug synthesis methods and proprietary carrier platforms. This comprehensive approach allows Rhegen to design and develop mRNA drugs for a variety of clinical indications, including functional protein defects, cancer, and infectious diseases. The firm has R&D and production centers in Shenzhen, Shanghai, and Wuhan.

Rhegen Bio's product pipeline is focused on several key areas: infectious disease vaccines, cancer immunotherapy, protein replacement therapies, and treatments for metabolic diseases. A notable achievement is the development of the world's first freeze-dried (lyophilized) mRNA vaccine for COVID-19's Omicron variant, a formulation that allows for long-term storage at standard refrigeration temperatures (2-8°C), addressing a major logistical challenge for mRNA vaccines. The company holds a significant intellectual property portfolio, with nearly 200 patent applications covering drug design, LNP delivery systems, and industrialization processes.